Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age



Status:Recruiting
Conditions:Infectious Disease
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:65 - 85
Updated:3/13/2019
Start Date:July 31, 2018
End Date:August 12, 2019
Contact:Pfizer CT.gov Call Center
Email:ClinicalTrials.gov_Inquiries@pfizer.com
Phone:1-800-718-1021

Use our guide to learn which trials are right for you!

A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE LOT CONSISTENCY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS 65 TO 85 YEARS OF AGE

This study will investigate a Clostridium difficile vaccine in healthy adults 65 to 85 years
of age, who will each receive 3 doses of vaccine. The study will assess the lot consistency,
safety, and tolerability of the vaccine, and also look at the subjects' immune response to
the vaccine.


Inclusion Criteria:

- Evidence of a personally signed and dated informed consent document.

- Willing and able to comply with study procedures.

- Healthy adults 65 to 85 years of age.

- Male subjects or female subjects who are not of childbearing potential.

- Ability to be contacted by telephone during study participation.

Exclusion Criteria:

- Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the investigator, or
subjects who are Pfizer employees, including their family members, directly involved
in the conduct of the study.

- Participation in other studies involving investigational drug(s)/vaccine(s) within 28
days prior to study entry through conclusion of the study.

- Previous administration of an investigational C difficile vaccine or C difficile
monoclonal antibody therapy.

- Proven or suspected prior episode of C difficile infection.

- Unstable chronic medical condition or disease requiring significant change in therapy
or hospitalization for worsening disease within 8 weeks before receipt of
investigational product.

- Serious chronic medical disorders, including metastatic malignancy, severe chronic
obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal
disease with or without dialysis, clinically unstable cardiac disease.

- Any bleeding disorder or anticoagulant therapy that would contraindicate intramuscular
injection.

- Any contraindication to vaccination or vaccine components, including previous
anaphylactic reaction to any vaccine or vaccine-related components.

- Subjects who may be unable to respond to vaccination due to:

- Congenital or acquired immunodeficiency.

- Receipt of systemic corticosteroids (greater than or equal to 20 mg/day of
prednisone or equivalent) for greater than or equal to 14 days within 28 days of
enrollment.

- Receipt of chronic systemic treatment with other known immunosuppressant
medications, or radiotherapy, within 6 months of enrollment.

- Underlying bone marrow disorder treated within the past year, such as
myelodysplasia, myeloma, or myeloproliferative disorder, treated within the past
year, or any history of bone marrow transplant.

- Malignancy that required treatment with chemotherapy (including the use of
adjunctive and hormonal therapy), immunotherapy, radiation therapy, or
antineoplastic target therapies within the past 24 months.

- Receipt of blood products or immunoglobulins within 6 months before enrollment through
conclusion of the study.

- Residence in a nursing home or other long-term care facility, or requirement for
semiskilled nursing care or assisted living. An ambulatory subject who lives in an
autonomous manner in a retirement home or village is eligible for the trial.

- A known infection with human immunodeficiency virus (HIV).

- Other acute or chronic medical or psychiatric condition including recent (within the
past year) or active suicidal ideation or behavioral or laboratory abnormality that
may increase the risk associated with study participation or investigational product
administration or may interfere with the interpretation of study results.

- Female subjects of childbearing potential; pregnant female subjects; breastfeeding
female subjects; fertile male subjects who are unwilling or unable to use a highly
effective method of contraception as outlined in this protocol for the duration of the
study and for at least 28 days after the last dose of investigational product.
We found this trial at
24
sites
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
860 Peachwood Drive
DeLand, Florida 32720
(386) 740-0770
Site Overview Avail Clinical Research is a renowned and experienced clinical research site conducting Phase...
?
mi
from
DeLand, FL
Click here to add this to my saved trials
4410 Medical Drive
San Antonio, Texas 78229
210-692-7157
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
1709 S Rock Rd
Wichita, Kansas 67207
316-689-6629
?
mi
from
Wichita, KS
Click here to add this to my saved trials
811 Juniper St NE
Atlanta, Georgia 30308
(404) 881-5800
Atlanta Center for Medical Research Welcome to the Atlanta Center for Medical Research, a leader...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Austin, Texas
?
mi
from
Austin, TX
Click here to add this to my saved trials
Charleston, South Carolina 29407
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Charlotte, North Carolina 28209
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
801 Monterey Street
Coral Gables, Florida 33134
?
mi
from
Coral Gables, FL
Click here to add this to my saved trials
?
mi
from
Draper, UT
Click here to add this to my saved trials
7261 Sheridan Street
Hollywood, Florida 33024
?
mi
from
Hollywood, FL
Click here to add this to my saved trials
Honolulu, Hawaii 96814
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
Meridian, Idaho 83642
?
mi
from
Meridian, ID
Click here to add this to my saved trials
Mobile, Alabama 36608
?
mi
from
Mobile, AL
Click here to add this to my saved trials
New Orleans, Louisiana 70121
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
Norfolk, Nebraska 68701
?
mi
from
Norfolk, NE
Click here to add this to my saved trials
3555 NW 58th St # 800
Oklahoma City, Oklahoma 73112
(405) 447-8839
Lynn Health Science Institute Our mission is to provide clinical trials research and health services...
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Omaha, Nebraska 68134
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Raritan, New Jersey 08869
?
mi
from
Raritan, NJ
Click here to add this to my saved trials
3652 Eureka Way
Redding, California 96001
?
mi
from
Redding, CA
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
South Jordan, UT
Click here to add this to my saved trials
Stockbridge, Georgia 30281
?
mi
from
Stockbridge, GA
Click here to add this to my saved trials
1907 Tradd Ct
Wilmington, North Carolina 28401
(910) 799-5500
PMG Research of Wilmington PMG Research of Wilmington has two offices situated in a 1...
?
mi
from
Wilmington, NC
Click here to add this to my saved trials